DUBLIN--(http://www.researchandmarkets.com/research/vfrlxn/global) has announced the addition of the "Global Biosimilars Industry" report to their offering.)--Research and Markets (
Biosimilar is a term used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. In 2009 alone, the total market caliber in US and five major European nations for biosimilars was $150.4 million and expanded to $198 million in the next 12 months which followed. It is also greatly anticipated that by 2015 the market worth of biosimilars is going to stretch up to $51 billion.
Even after the sanction of its pathways in US, EU and Japan and its growing capitalization, all of which help drive the biosimilar uptake, there still remain many detrimentals for it to achieve commercial success in developed markets. The exigency for cost-effective treatments still remains an issue to deal with. Concerns revolving comparability, brand loyalty, dearth of substitutes and competition from second generation brands are the crucial matters of contention for biosimilar market. Taking into account the emerging markets in countries such as Brazil, Russia, India and China, low purchasing power teamed with high proportion of out-of-pocket expense and not to mention brand loyalty, all hamper the growth of biosimilar market.
It is because of their intricacy, cost, and development risks that the manufacturing and commercialization in developed markets remains centered amongst a bunch of pharma companies, all of which are established generics corporations. These companies are now looking to accelerate the market for biosimilars by going into partnerships. With a solid foundation of reputation lodged, these corporations are hoping to take marketing of biosimilars to all new heights. There is hardly any doubt that these companies ought to accomplish their goals as they have been dominating the market ever since its establishment.
Meanwhile in the emerging markets, homegrown pharmaceutical companies dictate the biologics market and have launched numerous products which also play a hindrance for international corporations in entering the sector. Companies such as Biocon and Dr. Reddy's are looking forward to expand themselves through partnerships and uphold their revenues. With the accessing of biosimilar products readily growing globally, it only looks to rise by leaps and bounds in the coming times.
Key Topics Covered:
1. Executive Summary
2. What are Biosimilars?
3. Emergence of Biosimilars
4. Industry Definition
5. Overview of the Biopharmaceutical Industry
6. Global Biosimilars Market Statistics
7. Key Success Factors for Biosimilars
8. Factors Impacting the Global Biosimilars Industry
9. Biosimilar Market Drivers & Challenges
10. Regulatory Framework
11. Factors Determining Market Entry in the Global Biosimilar Industry
12. Biosimilar Approval Pathways in the US and Europe
13. Competitive Landscape
14. Analysis of Major Biosimilars
15. Upcoming Patent Expiries and Opportunities for Biosimilars
16. Strategies of Big Pharma to Combat Biosimilars
17. Country-wise Biosimilar Market Analysis
18. Major Industry Players
19. Global Biosimilars Market Outlook
- Dr. Reddy's Laboratories Limited
- Hospira Inc
- Sandoz International
- STADA Arzneimittel AG
- Teva Pharmaceutical Industries
- Watson Pharmaceuticals
- SBio Inc.
- Biocon Limited
- Biopartners Gmbh
- Celltrion Inc
- Intas Biopharmaceuticals
- Kyowa Hakko Kirin Co., Ltd.
- Reliance Life Sciences
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd
For more information visit http://www.researchandmarkets.com/research/vfrlxn/global